Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
07 07 2022
Historique:
received: 19 10 2021
revised: 16 02 2022
accepted: 25 04 2022
pubmed: 21 5 2022
medline: 14 7 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

Inflammation observed in SARS-CoV-2-infected patients suggests that inflammasomes, proinflammatory intracellular complexes, regulate various steps of infection. Lung epithelial cells express inflammasome-forming sensors and constitute the primary entry door of SARS-CoV-2. Here, we describe that the NLRP1 inflammasome detects SARS-CoV-2 infection in human lung epithelial cells. Specifically, human NLRP1 is cleaved at the Q333 site by multiple coronavirus 3CL proteases, which triggers inflammasome assembly and cell death and limits the production of infectious viral particles. Analysis of NLRP1-associated pathways unveils that 3CL proteases also inactivate the pyroptosis executioner Gasdermin D (GSDMD). Subsequently, caspase-3 and GSDME promote alternative cell pyroptosis. Finally, analysis of pyroptosis markers in plasma from COVID-19 patients with characterized severe pneumonia due to autoantibodies against, or inborn errors of, type I interferons (IFNs) highlights GSDME/caspase-3 as potential markers of disease severity. Overall, our findings identify NLRP1 as a sensor of SARS-CoV-2 infection in lung epithelia.

Identifiants

pubmed: 35594856
pii: S1097-2765(22)00433-6
doi: 10.1016/j.molcel.2022.04.033
pmc: PMC9108100
pii:
doi:

Substances chimiques

GSDMD protein, human 0
Inflammasomes 0
NLR Proteins 0
NLRP1 protein, human 0
Phosphate-Binding Proteins 0
Pore Forming Cytotoxic Proteins 0
Peptide Hydrolases EC 3.4.-
3C-like protease, SARS coronavirus EC 3.4.22.-
Caspase 3 EC 3.4.22.-
Coronavirus 3C Proteases EC 3.4.22.28

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2385-2400.e9

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Med. 2018 Aug;24(8):1151-1156
pubmed: 29967349
Life Sci Alliance. 2020 Apr 28;3(6):
pubmed: 32345661
C R Biol. 2021 Jun 21;344(1):19-25
pubmed: 34213846
Science. 2020 Dec 4;370(6521):
pubmed: 33093214
Nature. 2015 Oct 29;526(7575):660-5
pubmed: 26375003
Immunity. 2021 Jul 13;54(7):1447-1462.e5
pubmed: 33979579
Science. 2021 Jan 29;371(6528):
pubmed: 33243852
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Cell Chem Biol. 2017 Apr 20;24(4):507-514.e4
pubmed: 28392147
Cell Chem Biol. 2018 Mar 15;25(3):262-267.e5
pubmed: 29396289
Cell Rep. 2021 Apr 13;35(2):108998
pubmed: 33852854
EMBO Rep. 2020 Nov 5;21(11):e50829
pubmed: 33124769
Nature. 2021 Apr;592(7856):778-783
pubmed: 33731932
Cell. 2021 Jun 10;184(12):3178-3191.e18
pubmed: 34022140
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-18953
pubmed: 32699149
Trends Biochem Sci. 2021 Oct;46(10):848-860
pubmed: 34187722
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Cell Host Microbe. 2021 Oct 13;29(10):1521-1530.e10
pubmed: 34492225
J Virol. 2017 Aug 24;91(18):
pubmed: 28679757
Lancet Respir Med. 2021 Mar;9(3):223-224
pubmed: 33493449
Elife. 2021 Jan 07;10:
pubmed: 33410748
Elife. 2021 Apr 23;10:
pubmed: 33890574
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33231615
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Nat Commun. 2021 Aug 2;12(1):4664
pubmed: 34341353
J Virol. 2021 Jun 24;95(14):e0237420
pubmed: 33910954
Nat Commun. 2016 Jun 22;7:11929
pubmed: 27329339
Curr Opin Virol. 2021 Oct;50:119-127
pubmed: 34454352
BMC Bioinformatics. 2004 Jun 06;5:72
pubmed: 15180906
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413140
PLoS Pathog. 2016 Dec 7;12(12):e1006052
pubmed: 27926929
Virology. 2022 Mar;568:13-22
pubmed: 35066302
Cell Discov. 2021 Mar 23;7(1):17
pubmed: 33758165
Signal Transduct Target Ther. 2021 Mar 29;6(1):128
pubmed: 33776057
J Exp Med. 2021 Oct 4;218(10):
pubmed: 34357402
Nat Immunol. 2021 Jan;22(1):32-40
pubmed: 33277638
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31821443
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Nat Commun. 2019 May 7;10(1):2091
pubmed: 31064994
Science. 2003 Jun 13;300(5626):1763-7
pubmed: 12746549
Nat Immunol. 2014 Aug;15(8):727-37
pubmed: 24952505
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Nat Rev Immunol. 2021 Apr;21(4):245-256
pubmed: 33723416
Sci Immunol. 2019 Oct 25;4(40):
pubmed: 31653718
J Biol Chem. 2018 Dec 7;293(49):18864-18878
pubmed: 30291141
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Curr Opin Immunol. 2019 Oct;60:37-45
pubmed: 31121538
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
J Virol. 2021 Jan 29;:
pubmed: 33514628
Nat Struct Mol Biol. 2019 Sep;26(9):761-763
pubmed: 31477902
Nature. 2015 Oct 29;526(7575):666-71
pubmed: 26375259
Intensive Care Med. 2021 Jun;47(6):704-706
pubmed: 33835207
J Immunol. 2020 Jul 15;205(2):307-312
pubmed: 32493814
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33890986
Sci Rep. 2016 Feb 18;6:16836
pubmed: 26887506
Science. 2019 Apr 5;364(6435):
pubmed: 30872533
Cell. 2014 Mar 13;156(6):1193-1206
pubmed: 24630722
Nature. 2021 Mar;591(7848):131-136
pubmed: 33472215
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Science. 2019 Apr 5;364(6435):82-85
pubmed: 30872531
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Methods Mol Biol. 2018;1706:267-292
pubmed: 29423804
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413139
Nat Rev Immunol. 2016 Jul;16(7):407-20
pubmed: 27291964
Sci Transl Med. 2021 Sep 22;13(612):eabh2624
pubmed: 34429372
Blood. 2020 Jul 23;136(4):489-500
pubmed: 32492712

Auteurs

Rémi Planès (R)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France; InvivoGen, Toulouse, France; IRIM, University of Montpellier, CNRS, Montpellier, France. Electronic address: remi.planes@ipbs.fr.

Miriam Pinilla (M)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France; InvivoGen, Toulouse, France.

Karin Santoni (K)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Audrey Hessel (A)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Charlotte Passemar (C)

Molecular Immunity Unit, University of Cambridge Department of Medicine, MRC-Laboratory of Molecular Biology, Cambridge, UK.

Kenneth Lay (K)

Institute of Medical Biology, Agency of Science, Technology and Research, 8A Biomedical Grove, #06-06 Immunos, 138648 Singapore, Singapore; Laboratory of Human Genetics and Therapeutics, Genome Institute of Singapore (GIS), A(∗)STAR, Singapore, Singapore.

Perrine Paillette (P)

InvivoGen, Toulouse, France.

Ana-Luiza Chaves Valadão (AC)

IRIM, University of Montpellier, CNRS, Montpellier, France.

Kim Samirah Robinson (KS)

A(∗)STAR Skin Research Laboratories, 11 Mandalay Road, 308232 Singapore, Singapore.

Paul Bastard (P)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.

Nathaniel Lam (N)

University of Cambridge, Department of Veterinary Medicine, Cambridge CB30ES, UK; University of Cambridge, School of Clinical Medicine, Box 111, Cambridge Biomedical Campus, Cambridge CB2 0SP, UK.

Ricardo Fadrique (R)

Biological and Soft Systems, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK.

Ida Rossi (I)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

David Pericat (D)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Salimata Bagayoko (S)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Stephen Adonai Leon-Icaza (SA)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Yoann Rombouts (Y)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Eric Perouzel (E)

InvivoGen, Toulouse, France.

Michèle Tiraby (M)

InvivoGen, Toulouse, France.

Qian Zhang (Q)

University of Paris, Imagine Institute, Paris, France.

Pietro Cicuta (P)

Biological and Soft Systems, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK.

Emmanuelle Jouanguy (E)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.

Olivier Neyrolles (O)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Clare E Bryant (CE)

University of Cambridge, Department of Veterinary Medicine, Cambridge CB30ES, UK; University of Cambridge, School of Clinical Medicine, Box 111, Cambridge Biomedical Campus, Cambridge CB2 0SP, UK.

Andres R Floto (AR)

Molecular Immunity Unit, University of Cambridge Department of Medicine, MRC-Laboratory of Molecular Biology, Cambridge, UK.

Caroline Goujon (C)

IRIM, University of Montpellier, CNRS, Montpellier, France.

Franklin Zhong Lei (FZ)

A(∗)STAR Skin Research Laboratories, 11 Mandalay Road, 308232 Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, 308232 Singapore, Singapore; Skin Research Institute of Singapore (SRIS), 11 Mandalay Road, 308232 Singapore, Singapore.

Guillaume Martin-Blondel (G)

Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France.

Stein Silva (S)

Critical Care Unit, University Hospital of Purpan, Toulouse, France.

Jean-Laurent Casanova (JL)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA; Howard Hughes Medical Institute, New York, NY, USA.

Céline Cougoule (C)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Bruno Reversade (B)

Institute of Medical Biology, Agency of Science, Technology and Research, 8A Biomedical Grove, #06-06 Immunos, 138648 Singapore, Singapore; Laboratory of Human Genetics and Therapeutics, Genome Institute of Singapore (GIS), A(∗)STAR, Singapore, Singapore; Institute of Molecular and Cell Biology, 61 Biopolis Drive, 138673 Singapore, Singapore; Department of Paediatrics, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, 10 Medical Drive, 117597 Singapore, Singapore; The Medical Genetics Department, Koç University School of Medicine, 34010 Istanbul, Turkey.

Julien Marcoux (J)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

Emmanuel Ravet (E)

InvivoGen, Toulouse, France.

Etienne Meunier (E)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France. Electronic address: etienne.meunier@ipbs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH